Cleveland Clinic Installs OmniCorder's BioScanIR System to Monitor Response to Neoadjuvant Breast Cancer Therapy
Monday November 1, 8:00 am ET
EAST SETAUKET, N.Y--(BUSINESS WIRE)--Nov. 1, 2004--OmniCorder Technologies, Inc. (OTCBB Symbol: OMCT - News) today announced the delivery of a new cancer therapy monitoring configuration of its BioScanIR® System to The Cleveland Clinic. The system will be used to detect the effects of cancer treatments in patients undergoing neoadjuvant breast cancer therapy as part of a collaboration between OmniCorder Technologies and the Case Comprehensive Cancer Center, which includes The Cleveland Clinic Taussig Cancer Center and Case Western Reserve University School of Medicine.
The system, which has been specifically configured for this application, will be used as part of an international study to monitor breast cancer patients undergoing this new treatment protocol. This approach to breast cancer therapy which involves administering drug therapy prior to surgery seeks to reduce tumor size and improve a patient's chance for less-invasive, breast conserving surgery. An additional potential advantage of neoadjuvant cancer therapy is improved disease-free and overall survival. Critical to the successful implementation of this therapeutic approach is a means to detect patients' response to therapy and to monitor its continued effect.
Currently, the efficacy of this treatment is assessed by the imprecise measurement of physical examination, the invasive approach of repeated tumor biopsies, or the expensive and time-consuming technique of magnetic resonance imaging. The BioScanIR® System provides an innovative new approach for rapid, non-invasive and cost-effective imaging of therapy response. The BioScanIR® System does not require a contrast agent, does not use ionizing radiation and does not come into physical contact with the patient, making it an ideal imaging tool for the frequent imaging sessions required for this type of treatment. Using sophisticated sensor camera technology and DIRI® analysis methods, the system scans quickly and provides analysis in minutes.
"This pilot installation is the second in an expected series of international installations that will focus on cancer therapy of the breast," said Mark Fauci, OmniCorder's President and CEO. "We believe neoadjuvant therapy is one of the most promising new developments in the war against breast cancer and expect our functional imaging technology will have a significant impact on enabling the successful adoption of this less-invasive therapeutic approach."
About OmniCorder Technologies, Inc.:
OmniCorder Technologies, Inc., headquartered in East Setauket, New York, is a leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications.
OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications.
About The Cleveland Clinic:
The Cleveland Clinic is one of the four top hospitals in America, according to U.S. News & World Report's annual guide to "America's Best Hospitals." Founded in 1921 as a not-for-profit group practice, The Cleveland Clinic has grown into an international referral center with more than 1,000 doctors, offering world-class hospital and outpatient care in virtually every medical specialty. The Cleveland Clinic Taussig Cancer Center comprises a team of more than 250 expert physicians who provide a comprehensive approach to cancer treatment for any age group and any part of the body. The center offers a full range of services including cancer prevention, diagnosis, treatment and follow-up care. The Taussig Cancer Center participates in numerous clinical trials, providing patients with access to innovative treatments.
About Case Western Reserve University:
Case Western Reserve University is one of the nation's leading research universities that 50 years ago forged the curriculum that is today the world standard for medical education. Its has a rich history of medical research achievements from pioneering the use of ether as a general anesthetic (1847) and the use of gas anesthesia in surgical operations (1916) to creating the first artificial human chromosomes and offering a new approach to gene therapy and the treatment of a broad range of genetic diseases (1997).
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact:
OmniCorder Technologies, Inc.
Anne Marie Fields, 212-292-5710
afields@omnicorder.com
Source: OmniCorder Technologies, Inc. |
